AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNGX
  4. [Form 4] Soligenix, Inc. Insider Trading Activity

[Form 4] Soligenix, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing reveals that Robert J. Rubin, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

  • Granted 17,647 stock options to purchase common stock
  • Exercise price set at $1.70 per share
  • Options expire on June 20, 2035
  • Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This equity compensation grant aligns the director's interests with shareholders through a standard 10-year term and quarterly vesting schedule over one year. The transaction was reported in compliance with SEC Section 16 requirements for insider trading disclosure.

Il modulo 4 rivela che Robert J. Rubin, direttore di Soligenix, ha ricevuto una concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 17.647 opzioni su azioni per acquistare azioni ordinarie
  • Prezzo di esercizio fissato a 1,70 $ per azione
  • Scadenza delle opzioni il 20 giugno 2035
  • Il piano di maturazione avviene in quattro rate uguali: - 20 settembre 2025 - 20 dicembre 2025 - 20 marzo 2026 - 20 giugno 2026

Questa concessione di compensi azionari allinea gli interessi del direttore con quelli degli azionisti attraverso un periodo standard di 10 anni e un piano di maturazione trimestrale nell'arco di un anno. La transazione 猫 stata segnalata in conformit脿 ai requisiti della Sezione 16 della SEC per la divulgazione delle operazioni degli insider.

La presentaci贸n del Formulario 4 revela que Robert J. Rubin, director de Soligenix, recibi贸 una concesi贸n de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacci贸n con valores derivados incluyen:

  • Otorgamiento de 17,647 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $1.70 por acci贸n
  • Las opciones expiran el 20 de junio de 2035
  • El calendario de adquisici贸n ocurre en cuatro cuotas iguales: - 20 de septiembre de 2025 - 20 de diciembre de 2025 - 20 de marzo de 2026 - 20 de junio de 2026

Esta concesi贸n de compensaci贸n accionaria alinea los intereses del director con los de los accionistas mediante un plazo est谩ndar de 10 a帽os y un calendario de adquisici贸n trimestral durante un a帽o. La transacci贸n fue reportada en cumplimiento con los requisitos de la Secci贸n 16 de la SEC para la divulgaci贸n de operaciones internas.

Form 4 鞝滌稖靹滌棎 霐半ゴ氅�, Soligenix鞚� 鞚挫偓 Robert J. Rubin鞚� 2025雲� 6鞗� 20鞚� 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃姷雼堧嫟. 韺岇儩歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 17,647欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧赌瓴╈潃 欤茧嫻 1.70雼煬搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 20鞚�
  • 甓岆Μ旆摑 鞚检爼鞚� 4須岇棎 瓯胳硱 攴犽摫頃橁矊 鞚措（鞏挫: - 2025雲� 9鞗� 20鞚� - 2025雲� 12鞗� 20鞚� - 2026雲� 3鞗� 20鞚� - 2026雲� 6鞗� 20鞚�

鞚� 欤检嫕 氤挫儊 攵赌鞐姅 10雲勳潣 響滌 旮瓣皠瓿� 1雲� 霃欖晥 攵勱赴氤� 甓岆Μ旆摑 鞚检爼鞚� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜霌り臣 鞚检箻鞁滍偆電� 瓴冹瀰雼堧嫟. 鞚� 瓯半灅電� 雮措秬鞛� 瓯半灅 瓿奠嫓鞐� 甏�頃� SEC 靹轨厴 16 鞖旉贝鞚� 欷�靾橅晿鞐� 氤搓碃霅橃棃鞀惦媹雼�.

Le d茅p么t du formulaire 4 r茅v猫le que Robert J. Rubin, directeur chez Soligenix, a re莽u une attribution d'options d'achat d'actions le 20 juin 2025. Les d茅tails de la transaction sur titres d茅riv茅s comprennent :

  • Attribution de 17 647 options d'achat d'actions pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 1,70 $ par action
  • Les options expirent le 20 juin 2035
  • Le calendrier d'acquisition s'effectue en quatre versements 茅gaux : - 20 septembre 2025 - 20 d茅cembre 2025 - 20 mars 2026 - 20 juin 2026

Cette attribution de r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une dur茅e standard de 10 ans et un calendrier d'acquisition trimestriel sur un an. La transaction a 茅t茅 d茅clar茅e conform茅ment aux exigences de la section 16 de la SEC concernant la divulgation des op茅rations d'initi茅s.

Das Formular 4 zeigt, dass Robert J. Rubin, Direktor bei Soligenix, am 20. Juni 2025 eine Gew盲hrung von Aktienoptionen erhalten hat. Die Details der Derivatgesch盲fte umfassen:

  • Gew盲hrung von 17.647 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 1,70 $ pro Aktie
  • Optionen laufen am 20. Juni 2035 ab
  • Die Vesting-Plan erfolgt in vier gleichen Raten: - 20. September 2025 - 20. Dezember 2025 - 20. M盲rz 2026 - 20. Juni 2026

Diese Aktienverg眉tung richtet die Interessen des Direktors mit denen der Aktion盲re durch eine standardm盲脽ige Laufzeit von 10 Jahren und einen viertelj盲hrlichen Vesting-Zeitplan 眉ber ein Jahr aus. Die Transaktion wurde gem盲脽 den Anforderungen von Abschnitt 16 der SEC zur Offenlegung von Insidergesch盲ften gemeldet.

Positive
  • None.
Negative
  • None.

Il modulo 4 rivela che Robert J. Rubin, direttore di Soligenix, ha ricevuto una concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 17.647 opzioni su azioni per acquistare azioni ordinarie
  • Prezzo di esercizio fissato a 1,70 $ per azione
  • Scadenza delle opzioni il 20 giugno 2035
  • Il piano di maturazione avviene in quattro rate uguali: - 20 settembre 2025 - 20 dicembre 2025 - 20 marzo 2026 - 20 giugno 2026

Questa concessione di compensi azionari allinea gli interessi del direttore con quelli degli azionisti attraverso un periodo standard di 10 anni e un piano di maturazione trimestrale nell'arco di un anno. La transazione 猫 stata segnalata in conformit脿 ai requisiti della Sezione 16 della SEC per la divulgazione delle operazioni degli insider.

La presentaci贸n del Formulario 4 revela que Robert J. Rubin, director de Soligenix, recibi贸 una concesi贸n de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacci贸n con valores derivados incluyen:

  • Otorgamiento de 17,647 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $1.70 por acci贸n
  • Las opciones expiran el 20 de junio de 2035
  • El calendario de adquisici贸n ocurre en cuatro cuotas iguales: - 20 de septiembre de 2025 - 20 de diciembre de 2025 - 20 de marzo de 2026 - 20 de junio de 2026

Esta concesi贸n de compensaci贸n accionaria alinea los intereses del director con los de los accionistas mediante un plazo est谩ndar de 10 a帽os y un calendario de adquisici贸n trimestral durante un a帽o. La transacci贸n fue reportada en cumplimiento con los requisitos de la Secci贸n 16 de la SEC para la divulgaci贸n de operaciones internas.

Form 4 鞝滌稖靹滌棎 霐半ゴ氅�, Soligenix鞚� 鞚挫偓 Robert J. Rubin鞚� 2025雲� 6鞗� 20鞚� 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃姷雼堧嫟. 韺岇儩歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 17,647欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧赌瓴╈潃 欤茧嫻 1.70雼煬搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 20鞚�
  • 甓岆Μ旆摑 鞚检爼鞚� 4須岇棎 瓯胳硱 攴犽摫頃橁矊 鞚措（鞏挫: - 2025雲� 9鞗� 20鞚� - 2025雲� 12鞗� 20鞚� - 2026雲� 3鞗� 20鞚� - 2026雲� 6鞗� 20鞚�

鞚� 欤检嫕 氤挫儊 攵赌鞐姅 10雲勳潣 響滌 旮瓣皠瓿� 1雲� 霃欖晥 攵勱赴氤� 甓岆Μ旆摑 鞚检爼鞚� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜霌り臣 鞚检箻鞁滍偆電� 瓴冹瀰雼堧嫟. 鞚� 瓯半灅電� 雮措秬鞛� 瓯半灅 瓿奠嫓鞐� 甏�頃� SEC 靹轨厴 16 鞖旉贝鞚� 欷�靾橅晿鞐� 氤搓碃霅橃棃鞀惦媹雼�.

Le d茅p么t du formulaire 4 r茅v猫le que Robert J. Rubin, directeur chez Soligenix, a re莽u une attribution d'options d'achat d'actions le 20 juin 2025. Les d茅tails de la transaction sur titres d茅riv茅s comprennent :

  • Attribution de 17 647 options d'achat d'actions pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 1,70 $ par action
  • Les options expirent le 20 juin 2035
  • Le calendrier d'acquisition s'effectue en quatre versements 茅gaux : - 20 septembre 2025 - 20 d茅cembre 2025 - 20 mars 2026 - 20 juin 2026

Cette attribution de r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une dur茅e standard de 10 ans et un calendrier d'acquisition trimestriel sur un an. La transaction a 茅t茅 d茅clar茅e conform茅ment aux exigences de la section 16 de la SEC concernant la divulgation des op茅rations d'initi茅s.

Das Formular 4 zeigt, dass Robert J. Rubin, Direktor bei Soligenix, am 20. Juni 2025 eine Gew盲hrung von Aktienoptionen erhalten hat. Die Details der Derivatgesch盲fte umfassen:

  • Gew盲hrung von 17.647 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 1,70 $ pro Aktie
  • Optionen laufen am 20. Juni 2035 ab
  • Die Vesting-Plan erfolgt in vier gleichen Raten: - 20. September 2025 - 20. Dezember 2025 - 20. M盲rz 2026 - 20. Juni 2026

Diese Aktienverg眉tung richtet die Interessen des Direktors mit denen der Aktion盲re durch eine standardm盲脽ige Laufzeit von 10 Jahren und einen viertelj盲hrlichen Vesting-Zeitplan 眉ber ein Jahr aus. Die Transaktion wurde gem盲脽 den Anforderungen von Abschnitt 16 der SEC zur Offenlegung von Insidergesch盲ften gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RUBIN ROBERT J.
(Last) (First) (Middle)
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10
(Street)
PRINCETON NJ 08540
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.7 06/20/2025 A 17,647 (1) 06/20/2035 Common Stock 17,647 $0 17,647 D
Explanation of Responses:
1. The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026.
/s/ Robert J. Rubin 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did SNGX director Robert J. Rubin receive on June 20, 2025?

Robert J. Rubin received 17,647 stock options (right to buy) of SNGX common stock on June 20, 2025, with an exercise price of $1.70 per share.

What is the vesting schedule for SNGX director Rubin's stock options granted in June 2025?

The stock options vest in four equal installments on: September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.

When do the SNGX stock options granted to Robert Rubin expire?

The stock options expire on June 20, 2035, ten years after the grant date.

What is Robert J. Rubin's role at SNGX according to the Form 4?

According to the Form 4 filing, Robert J. Rubin serves as a Director of Soligenix, Inc. (SNGX).

What was the exercise price of the SNGX stock options granted to Robert Rubin in June 2025?

The exercise price (conversion price) of the stock options granted to Robert Rubin was $1.70 per share.
Stock SNGX logo
Soligenix Inc

NASDAQ:SNGX

SNGX Rankings

#10182 Ranked by Market Cap
N/A Ranked by Dividends

SNGX Latest News

Jul 31, 2025
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Beh莽et's Disease
Jul 8, 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Jul 1, 2025
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Jun 6, 2025
Soligenix Highlights Dr. Ellen Kim鈥檚 Recent Q&A and the Promise of HyBryte鈩� in Ongoing Clinical Trials
May 9, 2025
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

SNGX Latest SEC Filings

Jul 31, 2025
[8-K] Soligenix, Inc. Reports Material Event
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Soligenix, Inc. Insider Trading Activity
Jun 20, 2025
[S-8] Soligenix, Inc. Employee Benefit Plan Registration

SNGX Stock Data

4.08M
3.26M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
United States
PRINCETON